A Phase 2 interventional study of Acalabrutinib in COVID-19, sponsored by AstraZeneca. Completed at 50 sites in 14 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2021-09-17.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in COVID-19 by AstraZeneca — 1 open to participants now, 1 under way, 1 of them phase 3. COVID-19 · AstraZeneca.
Among the 43 studies in COVID-19 by AstraZeneca, this one is the 13th largest by enrollment of the 26 interventional ones that give a count, is one of 12 that started in 2020, is one of 5 in phase 2, and was the 1st registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →1 of the 43 studies in COVID-19 by AstraZeneca is open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Australia and 36 more countries
Ages 18+
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 8 · Phase 3 9 · Phase 4 1
First in 2020; this study’s year is marked. 12 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 177 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 147 across the 26 interventional studies, 4,232 across the 15 observational. Of the 38 that completed or were terminated, 17 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
1 of the studies in COVID-19 by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies in COVID-19 by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
CALAVI will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Acalabrutinib+ Best Supportive Care
Drug: Acalabrutinib
Best Supportive Care
Acalabrutinib- administered orally
Percentage of Participants Alive and Free of Respiratory Failure at Day 14
Respiratory failure, is defined based on resource utilization of any of the following modalities: a) Endotracheal intubation and mechanical ventilation b) Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates \>20 L/min with fraction of delivered oxygen ≥0.5) c) Non-invasive positive pressure ventilation or continuous positive airway pressure d) Extracorporeal membrane oxygenation
Time frame: At Day 14
Number of Participants With Adverse Events and Serious Adverse Events
Time frame: Screening to 28 (+3) days after last dose of acalabrutinib (for acalabrutinib + BSC participants) or to 38 (+3) days after randomization (for BSC alone participants)
Percentage of Participants Alive and Free of Respiratory Failure at Day 28
Respiratory failure, is defined based on resource utilization of any of the following modalities: a) Endotracheal intubation and mechanical ventilation b) Oxygen delivered by highflow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates \>20 L/min with fraction of delivered oxygen ≥0.5) c) Non-invasive positive pressure ventilation or continuous positive airway pressure d) Extracorporeal membrane oxygenation
Time frame: At Day 28
Percent Change From Baseline in C-reactive Protein.
Baseline is defined as the result obtained on the date of randomization. If no result was obtained on the date of randomization, the last result prior to the date of randomization is used. Percent change from baseline at Day X is calculated by multiplying the following result by 100%: (Day X value - Baseline value)/Baseline value. The mean of this result for all analyzed patients is taken to get the mean percent change from baseline.
Time frame: Days 3, 5, 7, 10, 14, 28
Percent Change From Baseline in Ferritin
Baseline is defined as the result obtained on the date of randomization. If no result was obtained on the date of randomization, the last result prior to the date of randomization is used. Percent change from baseline at Day X is calculated by multiplying the following result by 100%: (Day X value - Baseline value)/Baseline value. The mean of this result for all analyzed patients is taken to get the mean percent change from baseline.
Time frame: Days 3, 5, 7, 10, 14, 28
Percent Change From Baseline in Absolute Lymphocyte Count
Baseline is defined as the result obtained on the date of randomization. If no result was obtained on the date of randomization, the last result prior to the date of randomization is used. Percent change from baseline at Day X is calculated by multiplying the following result by 100%: (Day X value - Baseline value)/Baseline value. The mean of this result for all analyzed patients is taken to get the mean percent change from baseline.
Time frame: Days 3, 5, 7, 10, 14, 28
Overall Survival
Median overall survival, calculated using the Kaplan-Meier technique. Confidence interval for median overall survival (days) is derived based on Brookmeyer-Crowley method with log-log transformation.
Time frame: From randomization until 90 days after randomization. Safety Issue:
Percentage of Participants Alive and Discharged From ICU
Time frame: At Day 14 and at Day 28
Time From Randomization to First Occurrence of Respiratory Failure or Death on Study Due to Any Cause
Median time to first occurrence of respiratory failure or death, calculated using the Kaplan-Meier technique. Confidence interval for median overall survival (days) is derived based on Brookmeyer-Crowley method with log-log transformation.
Time frame: From randomization to 28 days after randomization.
Number of Days Alive and Free of Respiratory Failure
Respiratory failure, is defined based on resource utilization of any of the following modalities: a) Endotracheal intubation and mechanical ventilation b) Oxygen delivered by highflow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates \>20 L/min with fraction of delivered oxygen ≥0.5) c) Non-invasive positive pressure ventilation or continuous positive airway pressure d) Extracorporeal membrane oxygenation
Time frame: From randomization to 28 days after randomization.
Number of Days With Respiratory Failure
Respiratory failure, is defined based on resource utilization of any of the following modalities: a) Endotracheal intubation and mechanical ventilation b) Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates \>20 L/min with fraction of delivered oxygen ≥0.5) c) Non-invasive positive pressure ventilation or continuous positive airway pressure d) Extracorporeal membrane oxygenation For participants who die (due to any cause) prior to Day 28, days from death to Day 28 are counted as days with respiratory failure. For participants in hospital and experiencing respiratory failure at the time they withdraw from the study, days from last known status to Day 28 are counted as days with respiratory failure.
Time frame: From randomization to 28 days after randomization.
Number of Days Hospitalized
For this summary, the hospitalization must be considered clinically indicated to count as a day hospitalized. For participants who die (due to any cause) prior to Day 28, days from death to Day 28 are counted as days hospitalized. For participants in hospital at the time they withdraw from the study, days from last known status to Day 28 are counted as days hospitalized.
Time frame: From randomization to 28 days after randomization.
Number of Days in ICU
For this summary, the ICU stay must be considered clinically indicated to count as a day in ICU. For participants who die (due to any cause) prior to Day 90, days from death to Day 90 are counted as days in ICU.
Time frame: From randomization to 90 days after randomization.
Number of Days Alive Outside of Hospital
Time frame: From randomization to 28 days after randomization.
Number of Days Alive Outside of Hospital
Time frame: From randomization to 90 days after randomization.
Percent Change From Baseline in Oxygenation Index
Baseline is defined as the result obtained on the date of randomization. Percent change from baseline at Day X is calculated by multiplying the following result by 100%: (Day X value - Baseline value)/Baseline value. The mean of this result for all analyzed patients is taken to get the mean percent change from baseline.
Time frame: Days 3, 5, 7, 10, 14, 28
Time From Randomization to Clinical Improvement of at Least 2 Points on a 9-point Category Ordinal Scale
9-point category ordinal scale: 0. \* Uninfected, no clinical or virological evidence of infection 1. Ambulatory, no limitation of activities 2. Ambulatory, limitation of activities 3. Hospitalized - mild disease, no oxygen therapy 4. Hospitalized - mild disease, oxygen by mask or nasal prongs 5. Hospitalized - severe disease, non-invasive ventilation or high flow oxygen 6. Hospitalised - severe disease, intubation and mechanical ventilation 7. Hospitalized - severe disease, ventilation and additional organ support, such as pressors, renal replacement therapy, extracorporeal membrane oxygenation 8. Death Median time to first occurrence of respiratory failure or death, calculated using the Kaplan-Meier technique. Confidence interval for median overall survival (days) is derived based on Brookmeyer-Crowley method with log-log transformation.
Time frame: From randomization to 28 days after randomization.
Pharmacokinetics of Acalabrutinib
Summary of plasma concentrations (ng/mL) of acalabrutinib
Time frame: Day 3 and Day 7
Pharmacokinetics of ACP-5862
Summary of plasma concentrations (ng/mL) of ACP-5862
Time frame: Day 3 and Day 7
All participants had COVID-19 pneumonia (documented radiographically) requiring hospitalization and were recruited from the following countries: South Africa; India; Turkey; Japan; Russian Federation; France; Italy; Brazil; Argentina; Peru; Mexico; Chile. The first participant was randomized on 15 June 2020 and the last participant was randomized on 17 August 2020.
| Milestone | Acalabrutinib + BSC | BSC Alone |
|---|---|---|
| Started | 89 | 88 |
| Completed | 74 | 77 |
| Not completed | 15 | 11 |
| Withdrew: Death | 8 | 9 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Study terminated by sponsor incorrectly entered in database - participants completed the study | 2 | 0 |
| Withdrew: Withdrawal by subject | 5 | 1 |
Respiratory failure, is defined based on resource utilization of any of the following modalities: a) Endotracheal intubation and mechanical ventilation b) Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates \>20 L/min with fraction of delivered oxygen ≥0.5) c) Non-invasive positive pressure ventilation or continuous positive airway pressure d) Extracorporeal membrane oxygenation
| Percentage of participants | Acalabrutinib + BSC | BSC Alone |
|---|---|---|
| Percentage of Participants Alive and Free of Respiratory Failure at Day 14 | 83.1 (74.8 to 91.5) | 90.9 (84.3 to 97.5) |
| Participants | Acalabrutinib + BSC | BSC Alone |
|---|---|---|
| Any Adverse Event | 43 | 37 |
| Any Serious Adverse Event | 7 | 2 |
Respiratory failure, is defined based on resource utilization of any of the following modalities: a) Endotracheal intubation and mechanical ventilation b) Oxygen delivered by highflow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates \>20 L/min with fraction of delivered oxygen ≥0.5) c) Non-invasive positive pressure ventilation or continuous positive airway pressure d) Extracorporeal membrane oxygenation
| Percentage of participants | Acalabrutinib + BSC | BSC Alone |
|---|---|---|
| Percentage of Participants Alive and Free of Respiratory Failure at Day 28 | 84.3 (76.1 to 92.4) | 88.6 (81.4 to 95.8) |
Baseline is defined as the result obtained on the date of randomization. If no result was obtained on the date of randomization, the last result prior to the date of randomization is used. Percent change from baseline at Day X is calculated by multiplying the following result by 100%: (Day X value - Baseline value)/Baseline value. The mean of this result for all analyzed patients is taken to get the mean percent change from baseline.
| Percent change | Acalabrutinib + BSC | BSC Alone |
|---|---|---|
| Day 3 | -15.06 ± 95.82 | -15.25 ± 91.61 |
| Day 5 | -12.48 ± 113.38 | -41.07 ± 92.59 |
| Day 7 | -45.71 ± 106.84 | -23.41 ± 223.06 |
| Day 10/ Discharge (last post-baseline assessment if discharged from hospital prior to Day 10) | -16.84 ± 194.71 | -29.32 ± 166.35 |
| Day 10 | -35.53 ± 126.84 | -23.41 ± 203.02 |
| Day 14 | -12.49 ± 187.37 | -17.26 ± 256.87 |
| Day 28 | -30.28 ± 192.90 | -63.74 ± 75.28 |
Baseline is defined as the result obtained on the date of randomization. If no result was obtained on the date of randomization, the last result prior to the date of randomization is used. Percent change from baseline at Day X is calculated by multiplying the following result by 100%: (Day X value - Baseline value)/Baseline value. The mean of this result for all analyzed patients is taken to get the mean percent change from baseline.
| Percent change | Acalabrutinib + BSC | BSC Alone |
|---|---|---|
| Day 3 | 9.84 ± 92.66 | 6.49 ± 40.23 |
| Day 5 | 12.92 ± 105.09 | -12.76 ± 43.18 |
| Day 7 | -8.93 ± 53.52 | -8.79 ± 36.40 |
| Day 10/ Discharge (last post-baseline assessment if discharged from hospital prior to Day 10) | -9.09 ± 58.85 | 1.35 ± 125.95 |
| Day 10 | -5.99 ± 73.71 | 6.84 ± 178.23 |
| Day 14 | -18.81 ± 67.85 | -26.80 ± 46.10 |
| Day 28 | -66.82 ± 18.24 | -66.05 ± 21.67 |
Baseline is defined as the result obtained on the date of randomization. If no result was obtained on the date of randomization, the last result prior to the date of randomization is used. Percent change from baseline at Day X is calculated by multiplying the following result by 100%: (Day X value - Baseline value)/Baseline value. The mean of this result for all analyzed patients is taken to get the mean percent change from baseline.
| Percent change | Acalabrutinib + BSC | BSC Alone |
|---|---|---|
| Day 3 | 31.74 ± 59.32 | 36.82 ± 79.91 |
| Day 5 | 55.79 ± 101.57 | 87.25 ± 140.37 |
| Day 7 | 51.72 ± 91.82 | 79.33 ± 119.73 |
| Day 10/ Discharge (last post-baseline assessment if discharged from hospital prior to Day 10) | 78.34 ± 95.88 | 99.65 ± 149.02 |
| Day 10 | 98.55 ± 113.66 | 83.08 ± 105.56 |
| Day 14 | 74.65 ± 124.47 | 91.58 ± 123.63 |
| Day 28 | 89.35 ± 100.24 | 96.62 ± 97.30 |
Median overall survival, calculated using the Kaplan-Meier technique. Confidence interval for median overall survival (days) is derived based on Brookmeyer-Crowley method with log-log transformation.
| Days | Acalabrutinib + BSC | BSC Alone |
|---|---|---|
| Overall Survival | NA (NA to NA) | NA (NA to NA) |
| Percentage of participants | Acalabrutinib + BSC | BSC Alone |
|---|---|---|
| At Day 14 | 78.7 | 89.8 |
| At Day 28 | 83.1 | 87.5 |
Median time to first occurrence of respiratory failure or death, calculated using the Kaplan-Meier technique. Confidence interval for median overall survival (days) is derived based on Brookmeyer-Crowley method with log-log transformation.
| Days | Acalabrutinib + BSC | BSC Alone |
|---|---|---|
| Time From Randomization to First Occurrence of Respiratory Failure or Death on Study Due to Any Cause | NA (NA to NA) | NA (NA to NA) |
Respiratory failure, is defined based on resource utilization of any of the following modalities: a) Endotracheal intubation and mechanical ventilation b) Oxygen delivered by highflow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates \>20 L/min with fraction of delivered oxygen ≥0.5) c) Non-invasive positive pressure ventilation or continuous positive airway pressure d) Extracorporeal membrane oxygenation
| Days | Acalabrutinib + BSC | BSC Alone |
|---|---|---|
| Number of Days Alive and Free of Respiratory Failure | 24.8 ± 8.0 | 25.3 ± 7.1 |
Respiratory failure, is defined based on resource utilization of any of the following modalities: a) Endotracheal intubation and mechanical ventilation b) Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates \>20 L/min with fraction of delivered oxygen ≥0.5) c) Non-invasive positive pressure ventilation or continuous positive airway pressure d) Extracorporeal membrane oxygenation For participants who die (due to any cause) prior to Day 28, days from death to Day 28 are counted as days with respiratory failure. For participants in hospital and experiencing respiratory failure at the time they withdraw from the study, days from last known status to Day 28 are counted as days with respiratory failure.
| Days | Acalabrutinib + BSC | BSC Alone |
|---|---|---|
| Number of Days With Respiratory Failure | 3.2 ± 8.0 | 2.7 ± 7.1 |
For this summary, the hospitalization must be considered clinically indicated to count as a day hospitalized. For participants who die (due to any cause) prior to Day 28, days from death to Day 28 are counted as days hospitalized. For participants in hospital at the time they withdraw from the study, days from last known status to Day 28 are counted as days hospitalized.
| Days | Acalabrutinib + BSC | BSC Alone |
|---|---|---|
| Number of Days Hospitalized | 12.2 ± 8.6 | 10.4 ± 7.4 |
For this summary, the ICU stay must be considered clinically indicated to count as a day in ICU. For participants who die (due to any cause) prior to Day 90, days from death to Day 90 are counted as days in ICU.
| Days | Acalabrutinib + BSC | BSC Alone |
|---|---|---|
| Number of Days in ICU | 10.4 ± 25.5 | 9.7 ± 25.8 |
| Days | Acalabrutinib + BSC | BSC Alone |
|---|---|---|
| Number of Days Alive Outside of Hospital | 15.1 ± 8.4 | 17.0 ± 7.3 |
| Days | Acalabrutinib + BSC | BSC Alone |
|---|---|---|
| Number of Days Alive Outside of Hospital | 66.8 ± 28.2 | 71.3 ± 24.5 |
Baseline is defined as the result obtained on the date of randomization. Percent change from baseline at Day X is calculated by multiplying the following result by 100%: (Day X value - Baseline value)/Baseline value. The mean of this result for all analyzed patients is taken to get the mean percent change from baseline.
| Percent change | Acalabrutinib + BSC | BSC Alone |
|---|---|---|
| Day 3 | 11.65 ± 29.40 | 12.20 ± 33.88 |
| Day 5 | 23.94 ± 41.72 | 33.09 ± 51.50 |
| Day 7 | 30.58 ± 57.79 | 54.51 ± 84.75 |
| Day 10/ Discharge (last post-baseline assessment if discharged from hospital prior to Day 10) | 54.25 ± 71.71 | 62.10 ± 80.79 |
| Day 10 | 64.44 ± 84.02 | 80.52 ± 101.48 |
| Day 14 | 70.39 ± 77.27 | 83.71 ± 84.96 |
| Day 28 | 80.93 ± 89.61 | 90.68 ± 95.43 |
9-point category ordinal scale: 0. \* Uninfected, no clinical or virological evidence of infection 1. Ambulatory, no limitation of activities 2. Ambulatory, limitation of activities 3. Hospitalized - mild disease, no oxygen therapy 4. Hospitalized - mild disease, oxygen by mask or nasal prongs 5. Hospitalized - severe disease, non-invasive ventilation or high flow oxygen 6. Hospitalised - severe disease, intubation and mechanical ventilation 7. Hospitalized - severe disease, ventilation and additional organ support, such as pressors, renal replacement therapy, extracorporeal membrane oxygenation 8. Death Median time to first occurrence of respiratory failure or death, calculated using the Kaplan-Meier technique. Confidence interval for median overall survival (days) is derived based on Brookmeyer-Crowley method with log-log transformation.
| Days | Acalabrutinib + BSC | BSC Alone |
|---|---|---|
| Time From Randomization to Clinical Improvement of at Least 2 Points on a 9-point Category Ordinal Scale | 10.00 (8.00 to 12.00) | 10.00 (8.00 to 11.00) |
Summary of plasma concentrations (ng/mL) of acalabrutinib
| ng/mL | Acalabrutinib + BSC |
|---|---|
| Day 3, Pre-dose | 15.359 ± 195.1 |
| Day 3, 0.5 hours post-dose | 54.580 ± 139.7 |
| Day 3, 1 hour post-dose | 56.120 ± 141.6 |
| Day 3, 2 hours post-dose | 90.173 ± 104.3 |
| Day 3, 4 hours post-dose | 36.841 ± 179.2 |
| Day 3, 6 hours post-dose | 23.551 ± 205.0 |
| Day 7, 1 hour post-dose | 117.015 ± 60.3 |
| Day 7, 4 hours post-dose | 17.454 ± 108.6 |
Summary of plasma concentrations (ng/mL) of ACP-5862
| ng/mL | Acalabrutinib + BSC |
|---|---|
| Day 3, Pre-dose | 71.526 ± 94.8 |
| Day 3, 0.5 hours post-dose | 125.332 ± 109.9 |
| Day 3, 1 hour post-dose | 144.784 ± 95.1 |
| Day 3, 2 hours post-dose | 213.370 ± 72.7 |
| Day 3, 4 hours post-dose | 154.437 ± 70.3 |
| Day 3, 6 hours post-dose | 113.769 ± 82.8 |
| Day 7, 1 hour post-dose | 156.133 ± 68.0 |
| Day 7, 4 hours post-dose | 95.392 ± 69.7 |
Collected over Screening to 28 (+3) days after last dose of acalabrutinib (for acalabrutinib + BSC treated participants) or to 38 (+3) days after randomization (for BSC alone treated participants). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Acalabrutinib + BSC | 7/86 (8.1%) | 7/86 (8.1%) | 10/86 (11.6%) |
| BSC Alone | 10/91 (11%) | 2/91 (2.2%) | 2/91 (2.2%) |
| Event | Acalabrutinib + BSC | BSC Alone |
|---|---|---|
| PneumoniaInfections and infestations | 2/86 | 0/91 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/86 | 0/91 |
| Bacterial sepsisInfections and infestations | 1/86 | 0/91 |
| Mucosal infectionInfections and infestations | 1/86 | 0/91 |
| Acute kidney injuryRenal and urinary disorders | 1/86 | 0/91 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/86 | 0/91 |
| HypotensionVascular disorders | 1/86 | 0/91 |
| Septic shockInfections and infestations | 0/86 | 1/91 |
| Ischaemic strokeNervous system disorders | 0/86 | 1/91 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/86 | 1/91 |
| Event | Acalabrutinib + BSC | BSC Alone |
|---|---|---|
| HeadacheNervous system disorders | 10/86 | 2/91 |
| Age, Continuous(Years) | Acalabrutinib + BSC | BSC Alone | Total |
|---|---|---|---|
| Mean | 56.7 ± 13.3 | 56.7 ± 14.8 | 56.7 ± 14.1 |
| Age, Customized(Participants) | Acalabrutinib + BSC | BSC Alone | Total |
|---|---|---|---|
| < 65 years | 61 | 60 | 121 |
| >= 65 years | 28 | 28 | 56 |
| Sex: Female, Male(Participants) | Acalabrutinib + BSC | BSC Alone | Total |
|---|---|---|---|
| Female | 29 | 24 | 53 |
| Male | 60 | 64 | 124 |
| Race/Ethnicity, Customized(Participants) | Acalabrutinib + BSC | BSC Alone | Total |
|---|---|---|---|
| HISPANIC OR LATINO | 48 | 47 | 95 |
| NOT HISPANIC OR LATINO | 41 | 41 | 82 |
| NOT REPORTED | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Acalabrutinib + BSC | BSC Alone | Total |
|---|---|---|---|
| WHITE | 40 | 48 | 88 |
| BLACK OR AFRICAN AMERICAN | 3 | 5 | 8 |
| AMERICAN INDIAN OR ALASKA NATIVE | 7 | 3 | 10 |
| ASIAN | 23 | 13 | 36 |
| NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 0 | 0 | 0 |
| OTHER | 14 | 19 | 33 |
| NOT REPORTED | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jun 2020 to primary completion in Nov 2020, 5 months.
Results were first posted in Sep 2021, 9 months after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 5 months is below that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acalabrutinib